XML 38 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - AstraZeneca Agreements [Member] - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jul. 30, 2013
Jun. 30, 2016
Dec. 31, 2015
Jun. 30, 2015
Jun. 30, 2016
U.S./RoW [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expected upfront, non-contingent and time-based payments $ 374.0        
Upfront, non-contingent and time-based payments received   $ 62.0      
Development and regulatory approval milestones 550.0        
Commercial sales milestone 325.0        
Shared development costs     $ 233.0    
Additional consideration based on net sales description         Low 20% range
U.S./RoW [Member] | FibroGen, Inc. [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Shared development costs     $ 116.5    
U.S./RoW [Member] | Development Milestones [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Receipt of development milestone payment       $ 15.0  
China [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Development and regulatory approval milestones 161.0        
Commercial sales milestone 167.5        
Proceeds from upfront payments 28.2        
Contingent payment $ 20.0